ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).

Head and Neck Cancer

Anil D’Cruz, MD

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).

Hematologic Malignancies

Palliative Care

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Dec

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Community Oncology Report Showcases Barriers to Therapy Access, Staffing, and Clinical Trial Participation

FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma

Addition of Eflornithine to Lomustine in Patients With Recurrent Grade 3 Astrocytoma

Preoperative PAXG vs mFOLFIRINOX in Pancreatic Ductal Adenocarcinoma

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC